Results 91 to 100 of about 3,791 (213)

Long-term clinical outcomes of [177Lu]Lu-DOTATATE in patients with metastatic neuroendocrine tumors

Frontiers in Oncology
The incidence of gastroenteropancreatic neuroendocrine tumors has been rising and these tumors are usually only diagnosed at a metastatic stage.
Sabah Iqbal, Eric Zhuang, Moses Raj, Nathan Bahary, Dulabh K. Monga   +4 more
doaj   +1 more source

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.

Journal of Clinical Oncology, 2018
Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related QoL.
J. Strosberg, E. Wolin, B. Chasen, M. Kulke, D. Bushnell, M. Caplin, R. Baum, P. Kunz, T. Hobday, A. Hendifar, K. Oberg, M. Sierra, T. Thévenet, I. Margalet, P. Ruszniewski, E. Krenning   +15 more
semanticscholar   +1 more source

Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network

Journal of Nuclear Medicine
Visual Abstract A mesenteric mass (MM), characterized by fibrotic reaction, is present in most small-intestinal neuroendocrine tumors (SI-NETs).
L. Al Mansour, L. de Mestier, M. Haissaguerre, P. Afchain, J. Hadoux, Thierry Lecomte, D. Morland, A. Cottereau, Ophélie De Rycke, G. Tlili, Jérémie Tordo, Marc Janier, Agathe Deville, T. Walter   +13 more
semanticscholar   +1 more source

Enhancing precision: A predictive model for 177Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative 68Ga-DOTATATE PET and clinicopathological biomarkers

Theranostics
Purpose: This study aims to elucidate the role of quantitative SSTR-PET metrics and clinicopathological biomarkers in the progression-free survival (PFS) and overall survival (OS) of neuroendocrine tumors (NETs) treated with peptide receptor radionuclide
A. Akhavanallaf, Sonal Joshi, Arathi Mohan, Francis Worden, John C. Krauss, Habib Zaidi, Kirk A. Frey, Krithika Suresh, Y. Dewaraja, Ka Kit Wong   +9 more
semanticscholar   +1 more source

177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment

World Journal of Nuclear Medicine, 2019
Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have only a limited or no benefit from radioiodine therapy. For these patients, tyrosine kinase inhibitors have demonstrated encouraging results in advanced RrDTC.
Majid Assadi, Hojjat Ahmadzadehfar
doaj   +1 more source

Predicting the Response of Patients Treated with ¹⁷⁷Lu-DOTATATE Using Single-photon Emission Computed Tomography-Computed Tomography Image-based Radiomics and Clinical Features. [PDF]

J Med Signals Sens
Background: In this study, we want to evaluate the response to Lutetium-177 (177Lu)-DOTATATE treatment in patients with neuroendocrine tumors (NETs) using single-photon emission computed tomography (SPECT) and computed tomography (CT), based on image ...
Behmanesh B, Abdi-Saray A, Deevband MR, Amoui M, Haghighatkhah HR, Shalbaf A.   +5 more
europepmc   +2 more sources

Maximum tumor diameter and renal function can predict the declining surface dose rate after ¹⁷⁷Lu-Dotatate: preliminary results of single institution in Japan. [PDF]

Jpn J Radiol
This study aimed to develop a user-friendly prediction formula for dose rate adjustment after initial 177Lu-Dotatate therapy from a prospective observational study of patients.
Ono T, Ichikawa M, Tanada T, Kanezawa C, Sato H.   +4 more
europepmc   +2 more sources

Global insights into [177Lu]Lu-DOTATATE safety: a comprehensive disproportionality analysis from the WHO pharmacovigilance database

Scientific Reports
Peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE is an effective treatment for metastatic or inoperable neuroendocrine tumors. While clinical trials have demonstrated its efficacy and safety in a limited number of selected patients, real ...
Typhanie Ladrière, Basile Chrétien, Anne-Laure Bignon, Karine Bouhier-Leporrier, Charles Dolladille, Jonathan Vigne   +5 more
doaj   +1 more source

Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer

Case Reports in Oncology, 2019
The field of theranostics is a new nuclear medicine tool being utilized in the treatment of different types of cancers. It couples receptor-specific based imaging predicting and guiding response to receptor-specific based radionuclide therapies.
Pashtoon M. Kasi, Akash Sharma, Manoj K. Jain   +2 more
doaj   +1 more source

Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response

Frontiers in Immunology
Ionizing radiation has garnered considerable attention as a combination partner for immunotherapy due to its potential immunostimulatory effects. In contrast to the more commonly used external beam radiation, we explored the feasibility of combining ...
Yanping Yang, Yanping Yang, Yogindra Vedvyas, Yogindra Vedvyas, Yago Alcaina, Ju Y. Son, Irene M. Min, Irene M. Min, Moonsoo M. Jin, Moonsoo M. Jin   +9 more
doaj   +1 more source